about
Diabetic neuropathic pain: Physiopathology and treatmentTapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patientsTapentadol for Cancer Pain Management: A Narrative Review.Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice.Treatment for chronic low back pain: the focus should change to multimodal management that reflects the underlying pain mechanisms.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.
P2860
Q27004604-834F92BD-1FBF-4572-8D71-6CCAB39AE8A1Q34783638-4E151C72-3F7A-42FA-BDB2-22555F121428Q36248445-270E6077-1DBD-4A7B-A190-05EA25D99FD7Q38244605-3A9ED3A1-B3D1-431A-9538-13D07D6E06D7Q38508009-8106B1B4-4CDF-49A6-8D5A-AE128375FA4BQ40701683-580A420A-5D9F-4F5C-AB6E-F6CE74423DA0Q47321593-D11C15A4-B467-4838-A6A7-FEE6AED0FB73Q52603231-54341C38-466E-4853-9D03-F6B512438264
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tapentadol extended release for chronic pain patients.
@en
type
label
Tapentadol extended release for chronic pain patients.
@en
prefLabel
Tapentadol extended release for chronic pain patients.
@en
P2093
P2860
P1433
P1476
Tapentadol extended release for chronic pain patients.
@en
P2093
Joseph V Pergolizzi
Robert B Raffa
Robert Taylor
P2860
P2888
P356
10.1007/S12325-013-0002-Y
P407
P577
2013-01-15T00:00:00Z
P6179
1013415281